Press Releases September 1, 2026 07:00 AM

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Tango Therapeutics Announces Participation in 2026 Cantor Global Healthcare Conference Fireside Chat

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
TNGX

Tango Therapeutics, a clinical-stage biotech company focused on precision oncology therapies, will present at the 2026 Cantor Global Healthcare Conference. The company is advancing cancer treatments through synthetic lethality targets and will webcast its management discussion.

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
TNGX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Tango Therapeutics is a clinical-stage biotechnology company developing precision medicines for cancer treatment.
  • The company leverages synthetic lethality to discover novel drug targets critical to cancer.
  • Tango will participate in a widely followed global healthcare conference with a live and replay webcast accessible to investors.

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.

The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investors:
Elizabeth Hickin
ehickin@tangotx.com

Media:
1AB
Amanda Lazaro
amanda@1abmedia.com


Risks

  • As a clinical-stage biotech, Tango is subject to risks related to drug development timelines and regulatory approvals.
  • Market and investor response can be sensitive to presentation details and clinical progress updates.
  • The oncology biotechnology sector is competitive and dependent on scientific breakthroughs and patent protections.

More from Press Releases

Lorenzo Grandi, STMicroelectronics’ President and CFO to speak at Citi investor conference Sep 2, 2026 Skyworks Announces Extension of Expiration Date of Exchange Offers for Qorvo’s Senior Notes due 2029 and 2031 Sep 1, 2026 Quantumsphere Acquisition Corporation Announces Termination of the Agreement and Plan of Merger with SACH Pte. Ltd. Sep 1, 2026 Enovix’s TAA-Compliant Battery Manufacturing Strengthens Position with U.S. Defense Supply Chain Sep 1, 2026 Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange Sep 1, 2026